Introduction
Obesity is a rapidly increasing public health concern in India, affecting over 135 million individuals. The ICMR-INDIAB study reports abdominal obesity prevalence ranging from 16.9% to 36.3%, with higher burden in urban populations.1 This rise is strongly associated with sedentary lifestyles, dietary transitions, and increased consumption of processed foods. Beyond metabolic risk, obesity contributes to psychosocial distress, reduced productivity, and increased healthcare burden. Given these challenges, Ayurvedic interventions are being revisited for their holistic and individualized approach to metabolic disorders.
Ayurvedic perspective on obesity
In Ayurveda, obesity is described as Sthaulya or Medoroga, resulting from imbalance of Vata, Pitta, and Kapha doshas, with predominant Kapha and Meda dhatu vitiation. Classical texts by Acharya Charaka and Sushruta classify Sthaulya as a pathological condition associated with chronic ill health. The disorder arises due to impaired Agni, leading to accumulation of Ama and dysregulated lipid metabolism. Central to its pathogenesis is dysfunction of Medo-dhatvagni, resulting in excessive adipose tissue deposition and systemic metabolic imbalance. Management focuses on correcting doshic imbalance through diet, lifestyle modification, and herbal formulations.
Ayurvedic therapeutic formulations
Vyoshadi Guggulu (VSG) and Vidanga Churna (VDC) are widely used anti-obesity formulations. VSG contains ingredients such as Commiphora mukul, Zingiber officinale, and Terminalia chebula, which possess Lekhaniya, Kapha-pacifying, and metabolic-enhancing properties. VDC, primarily composed of Embelia ribes, exhibits lipid-lowering and anti-obesity activity.2 Both formulations are believed to enhance Agni, reduce Ama accumulation, and improve lipid mobilization.
Pharmacological and experimental evidence
Vidanga demonstrates anti-adipogenic, antioxidant, and lipid-lowering effects, with embelin showing reductions in cholesterol, triglycerides, and insulin resistance in preclinical models. Guggulu exhibits well-documented hypolipidemic, anti-inflammatory, and metabolic regulatory effects, with clinical studies reporting improvements in BMI and waist circumference.3 However, most available evidence is derived from preclinical studies or single-ingredient evaluations, with limited data on standardized combination formulations and long-term clinical outcomes.
Clinical evidence and translational relevance
Despite promising preclinical and traditional evidence, clinical validation of Ayurvedic polyherbal formulations in obesity remains limited. Most existing studies on Vyoshadi Guggulu (VSG) and Vidanga Churna (VDC) are small-scale, open-label, or single-arm trials, often lacking rigorous randomization and long-term follow-up. Reported outcomes generally indicate modest but consistent reductions in body weight, body mass index (BMI), and waist circumference, along with improvements in lipid parameters such as total cholesterol, low-density lipoprotein (LDL), and triglycerides. However, heterogeneity in study design, dosing regimens, and formulation standardization limits direct comparability of findings.
Emerging clinical observations suggest that the combined use of VSG and VDC may exert synergistic metabolic effects by simultaneously targeting multiple pathogenic pathways involved in obesity, including adipogenesis, lipid accumulation, and impaired digestive metabolism. This multimodal action aligns with the Ayurvedic concept of restoring Agni and reducing Meda dhatu excess, while also corresponding to modern mechanistic insights such as modulation of lipid metabolism and inflammatory mediators. Nevertheless, robust evidence from multicenter randomized controlled trials is still required to establish definitive efficacy.
Safety and tolerability profile
Ayurvedic polyherbal formulations are generally considered safe when administered in classical doses and under appropriate supervision. Reported adverse effects with VSG and VDC are typically mild and transient, including gastrointestinal discomfort such as nausea, abdominal bloating, or loose stools. However, variability in preparation methods and lack of stringent standardization across commercial products raise concerns regarding consistency in safety profiles. In addition, potential herb–drug interactions, particularly in patients concurrently receiving antihyperlipidemic or antidiabetic medications, warrant careful monitoring.
Biochemical safety assessments in available studies have not demonstrated significant hepatotoxicity or nephrotoxicity, although systematic long-term safety data remain insufficient. Therefore, periodic monitoring of liver function tests, renal parameters, and metabolic markers is recommended during extended therapy.
Mechanistic integration of Ayurvedic and modern perspectives
From a mechanistic standpoint, VSG and VDC may exert anti-obesity effects through complementary biological pathways. These include inhibition of adipocyte differentiation, enhancement of lipid catabolism, improvement in insulin sensitivity, and modulation of oxidative stress. Compounds such as guggulsterones and embelin are implicated in nuclear receptor signaling pathways, including peroxisome proliferator-activated receptors (PPARs), which regulate lipid and glucose homeostasis. Additionally, antioxidant activity may contribute to reduced chronic low-grade inflammation, a key driver of obesity-associated metabolic dysfunction.
This integrative understanding bridges Ayurvedic concepts such as Kapha pacification and Medo dhatu reduction with contemporary metabolic frameworks, supporting the rationale for multi-targeted therapeutic strategies in obesity management.
Limitations and future directions
Current evidence is limited by small sample sizes, short intervention durations, and lack of standardized outcome measures.4 Furthermore, variability in herbal composition, extraction methods, and bioactive compound quantification remains a significant challenge. Future research should focus on well-designed randomized controlled trials, standardized formulation development, pharmacokinetic profiling, and identification of active constituents responsible for clinical effects.
Conclusion
Ayurvedic polyherbal formulations such as Vyoshadi Guggulu and Vidanga Churna demonstrate promising anti-obesity potential through multi-target metabolic actions. While preliminary evidence supports their efficacy and favorable safety profile, definitive clinical validation through large-scale, methodologically robust studies is essential to establish their role as evidence-based adjuncts in obesity management.
References:
- Pradeepa R, Anjana RM, Joshi SR, et al. Prevalence of generalized & abdominal obesity in urban & rural India--the ICMR-INDIAB Study (Phase-I) [ICMR- NDIAB-3]. Indian J Med Res. 2015;142(2):139-150. doi:10.4103/0971-5916.164234. https://pmc.ncbi.nlm.nih.gov/articles/PMC4613435/
- Durg S, Veerapur VP, Neelima S, Dhadde SB. Antidiabetic activity of Embelia ribes, embelin and its derivatives: A systematic review and meta-analysis. Biomed Pharmacother. 2017;86:195-204. doi:10.1016/j.biopha.2016.12.001. https://pubmed.ncbi.nlm.nih.gov/27984799/
- Mahajon B, Krishna CM, Debnath SK, Subhose V, Rath KK, Anumol K, Maheswar T, Sharma BS, Khanduri S, Tripathi A, Rana R. Efficacy and safety of Ayurveda compound formulations in Sthoulya (obesity) management: a multi-centric clinical trial. (2025): 867-885. https://www.cabidigitallibrary.org/doi/full/10.5555/20250221137
- Giri SK, Vedi SK, Doddamani S, et al. Clinical Safety and Efficacy of Ayurveda Multi-Herbal Formulation in the Management of Obesity. Glob Adv Integr Med Health. 2025;14:27536130251356447. Published 2025 Jul 2. doi:10.1177/27536130251356447. https://pmc.ncbi.nlm.nih.gov/articles/PMC12231980/